Breast cancer (Bc) is the most common female malignant tumor worldwide. The mechanism of tumorigenesis is still unclear. Ras-related proteins in brain (Rab)22a belongs to the Ras superfamily, which may act as an oncogene and participate in carcinogenesis. The present study aims to identify whether Rab22a could be a novel biomarker of prognosis and determine the effects of Rab22a on Bc cell progression. A total 258 BC and 56 para-tumor or non-tumor formalin fixed paraffin embedded tissues were stained through immunohistochemistry. The association between Rab22a expression and clinicopathological features, as well as overall survival status were analyzed. The expression level of Rab22a in breast cell lines were detected using reverse transcription-quantitative PcR and western blotting. SK-BR-3 cells were infected with Rab22a short hairpin RNA lenti-virus and the ability of cell proliferation, migration and invasion were measured. Gene Set Enrichment Analysis (GSEA) was employed to analyze the pathways involved in the Rab22a mRNA high level group. Rab22a was found to be overexpressed in BC tissues and upregulated in BC cells. High expression of Rab22a was related to a poor prognosis of patients with Bc. Knockdown of Rab22a decreased the proliferation, migration and invasion ability of Bc cells. GSEA indicated that certain pathways, including mammalian target of rapamycin complex 1 and protein secretion were upregulated, while pathways, such as hypoxia and KRas were downregulated in the Rab22a high level group. Rab22a is of prognostic value for Bc and necessary for Bc cell proliferation.
Introduction
Breast cancer (Bc) is the most prevalent malignant tumor among females worldwide. It is the most common cancer in china, as well as the United States (1). Fan et al (2) reported that chinese patients account for over 12% of all newly diagnosed cases as well as 9% of all deaths from Bc globally. Similarly, Waks and Winer (3) reported that >250,000 new patients were diagnosed in the United States in 2017 and they estimated that 12% of women over the course of their lifetimes will be diagnosed with Bc. depending on levels of estrogen or progesterone receptors (ER and PR, respectively), human epidermal growth factor-2 (Her-2), as well as Ki-67, BC is classified into four major molecular subtypes: Luminal A, Luminal B, Her-2 positive and basal-like. Although the diagnosis, as well as treatment of BC has achieved significant advances and overall survival (OS) has improved during recent decades, there are still challenges regarding the early detection and prediction of survival in Bc. Moreover, the mechanism of tumorigenesis is still unclear. Thus, it is important to develop novel biomarkers for diagnosis and prognosis, as well as treatment targets.
The authors' previous study reported that Rab22a is the target gene of microRNAs (miRNAs/miR)-193b in Bc (4) . Studies of miRNAs have reported that miR-520b (5), miR-204 (6) and miR-203 (7) are downregulated in Bc or other types of tumors. In addition, one of the potential targeting genes of the above-mentioned miRNAs is Rab22a, which was confirmed using a luciferase assay and is upregulated in these tumor tissues or cell lines. All these findings lead to the conclusion that Rab22a may act as an oncogene and participate in carcinogenesis. Furthermore, emerging evidence suggests that dysregulated expression of Rab22a affects tumor growth. He et al (8) found that Rab22a is upregulated in most of the 11 hepatocellular carcinomas, as well as 1 case of cholangiohepatoma. Okamoto et al (9) identified that Rab22a is positively expressed in malignant melanoma cell lines and situated at the areas of chromosomal breakpoints.
The coding gene of Rab22a, which belongs to the Ras superfamily, is located at chromosome 20q13. 32 . Rab22a is a part of the Ras-related proteins in brain (Rabs) GTPase subfamily, which are small GTP-binding proteins. Zhou et al (10) reported that Rab22a participates at several levels of the endocytic pathway. In addition, the composition of the plasma membrane receptors is regulated by endocytic recycling and endocytic uptake. Stenmark concluded that Rab22a mediates trafficking among trans-Golgi network and early endosomes (11) . Kauppi et al (12) reported that the overexpression of Rab22a in vitro leads to the enlargement of early endosomes. Previous studies have also indicated that the recycling of the transferrin receptor and major histocompatibility complex-Ⅰ (MHC)-Ⅰ by endocytosed cargos is blocked by small interfering RNAs that inhibit the function of Rab22a (13, 14) . It is widely reported that dysregulation of endocytosis is the hallmark of several cancers. Therefore, the abnormal expression of Rab GTPases may be involved in tumorigenesis.
Wang et al (15) reported that the upregulation of Rab22a mRNA in the primary tumor is related to worsening of overall as well as metastasis-free survival, by analyzing The cancer Genome Atlas (TcGA) database of patients with Bc. An additional study found that knockdown of Rab22a inhibits Bc metastasis in vivo (15) . Kang et al (16) designed and synthesized O(2)-3-Aminopropyl diazeniumdiolates 3a-f, which prevents the growth and metastasis of triple negative Bc in vivo as well as in vitro by MHc-I impairing microvesicle formation by altering the expression of miR-203/Rab22a in a nitric oxide-dependent manner.
Although much of the research indicates that the Rab22a gene can function as an oncogene in several cancer models and indicates its potential therapy target (15, 16) , whether Rab22a may be developed as a novel prognostic biomarker in Bc is not well understood. The current study applied immunohistochemistry (IHc) staining and analyzed the association between Rab22a expression and clinicopathological features, as well as OS status. The impact of Rab22a on the progression of Bc cells as well as the probable pathways involved was also studied.
Materials and methods
Patients and samples. A total of 258 samples from female patients with Bc aged from 27 to 78, who had accepted modified radical mastectomy or breast-conserving surgery at the china-Japan Union Hospital of Jilin University from January 2012 to december 2013 were included in the present study. Patient characteristics are shown in Table I . The clinical stage was distinguished using the guidelines of the American Joint committee on cancer. The patients who accepted chemotherapy or radiotherapy and hormone therapy prior to surgery were excluded. Recurrent or metastasis cases at the time of diagnosis were eliminated as well. The last date of follow-up was in April 2019. A total of 56 para-tumor or non-tumor tissues were acquired as the controls. The current study was conducted after obtaining written informed consent from all patients and was approved by the Research Ethics committee of the china-Japan Union Hospital of Jilin University (approval no. 2019022603).
Breast cell lines. The human mammary gland epithelium cell line, McF-10A was cultured in a dMEd/HAM F12 1:1 mixed medium (Hyclone; GE Healthcare), which contains 5% horse serum (Gibco; Thermo Fisher Scientific, Inc.), 0.5 mg/ml hydrocortisone (Sigma-Aldrich; Merck KGaA), 100 ng/ml cholera toxin (Sigma-Aldrich; Merck KGaA), 10 µg/ml insulin (Sigma-Aldrich; Merck KGaA) and 20 ng/ml EFG (Peprotech, Inc.). The human Bc cell lines, McF-7 as well as SK-BR-3, were cultured in dMEM H21 (Hyclone; GE Healthcare) and RPMI-1640 (Hyclone; GE Healthcare), each supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 mg/ml streptomycin. All cell lines were bought from American Type Culture Collection and cultured at 37˚C with 5% cO 2 , in a humidified atmosphere.
IHC staining. In order to identify Rab22a expression levels in the Bc tissues, IHc staining was performed by following the manufacturer's protocol (Metal enhanced dAB for IHc; Invitrogen; Thermo Fisher Scientific, Inc.). In brief, after fixation with formalin at room temperature for 48 h and embedded with paraffin, 3 µm thick paraffin sections adhered to slides were incubated at 65˚C for 30 min, deparaffinized using xylene and then rehydrated using alcohol. The slides were submerged in EDTA for antigen retrieval. Next, the sections were treated with 3% hydrogen, heated in a microwave at 100˚C for 5 min and incubated in 1% bovine serum albumin (Gibco; Thermo Fisher Scientific, Inc.). Following this, they were incubated with a Rab22a antibody (cat. no. 12125-1-AP; Proteintech, Inc.) at dilution of 1:100 overnight at 4˚C. Normal goat serum served as the negative control. After washing with PBS+1% Tween, the sections were incubated with the secondary antibody with streptavidin-horseradish peroxidase complex (cat. no. 31460; Invitrogen; Thermo Fisher Scientific, Inc.) at a dilution of 1:2,000 at room temperature for 1 h, followed by colorimetric detection using metal enhanced dAB (cat. no. 34065; Invitrogen; Thermo Fisher Scientific, Inc.) at room temperature for 5 min. All sections were submerged in 3-amino-9-ethyl carbazole, counterstained using 10% Mayer's hematoxylin at room temperature for 2 min, dehydrated and mounted.
The intensity of IHc staining of the sections was evaluated using a light microscope at x100 magnification by two senior pathologists independently, who were not aware of the patient information and histopathological details. The plasma staining of Rab22a was positive. The staining intensity as well as positive staining percentage of tumor cells were used for evaluation. The intensity of staining was categorized as previously described (17) : 0 (stainless), 1 (light yellow), 2 (yellow brown) and 3 (brown). The proportion of positive staining tumor cells were 0 (0%), 1 (1-10%), 2 (11-25%), 3 (25-50%) and 4 (>50%). The score was calculated as staining intensity x proportion of positive cells and was used as the staining index to calculate IHC intensity (range from 0 to 12). A staining index score of 0 was defined as no expression of Rab22 (-), 1-3 signified low expression of Rab22 (1+), 4-6 signified mild expression of Rab22a (2+), while >6 signified high expression of Rab22a (3+).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA extraction was done using TRIzol (Ambion; Thermo Fisher Scientific, Inc.). The reverse transcription of total RNA was done using 5X PrimeScript RT Master Mix for Real Time (Takara Bio, Inc.). RT-qPCR was performed using SYBR ® Premix DimerEraser™ Perfect Real Time (Takara Bio, Inc.). The operation process was conducted following the manufacturer's protocol. RT-qPcR analyses were conducted by Mastercycler (Eppendorf). The thermocycling procedure was as follows: 30 sec at 95˚C, followed by 40 cycles of 95˚C for 30 sec, 57˚C for 30 sec and a final step of 68˚C for 30 min. The primer sequences used were as follows: Rab22a F: 5'-GTc ccT TAG cAc cAA TGT AcT ATc-3', R: 5'-AAT GGc AAc TAc AAT ATT AGG TGG-3'; GAPdH F: 5'-GAA GGc TGG GGc TcA TTT GcA GGG-3', R: 5'-GGT GcA GGA GGc ATT GcT GAT GAT-3'. The comparative fold-change at mRNA level was calculated Table I . clinicopathological characteristics of patient samples and expression of Rab22a in breast cancer. Table I . compared with the 56 cases of nearby non-tumor breast tissues, in which Rab22a is untraceable or is expressed at low levels, Rab22a was found to be overexpressed in BC tissues. Rab22a expression in cancer tissues was successfully identified in 3 levels, including low expression (1+) in 30 cases, mild expression (2+) in 125 cases and high expression (3+) in 103 cases (Fig. 1) . GEO datasets were employed to verify Rab22a expression. Rab22a expression was significantly increased in tumor samples, compared with normal samples ( Fig. 2A and B ). Furthermore, Rab22a
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expression was significantly increased in all four molecular subtypes (Luminal A and B, Her-2 and basal-like) compared with normal tissues (Fig. 2c ). (Table I) . Rab22a expression was found to be related with age at menarche (P=0.005), clinical stage (P= 0.001), N classification (P= 0.013), nipple invasion (P= 0.042), venous invasion (P=0.044) and vital states (P=0.003). There was no difference based on age, menopause stage, T classification, nerve invasion, basal invasion, pectoralis minor muscle invasion, pathological differentiation, ER status, PR status, expression of Her-2, expression of Ki67 and molecular classification among the levels of Rab22a expression. Spearman analysis of correlation among Rab22a and clinicopathological features indicate that the expression of Rab22a is significantly positively associated with age at menarche (P=0.002), clinical stage (P=0.001), T classification (P=0.006), N classification (P=0.008), nipple invasion (P=0.015), venous invasion (P=0.014), expression of Her-2 (P=0.038) and molecular classification (P=0.006), while negatively associated with vital states (P=0.006) (Table II) .
Rab22a overexpression is correlated with the clinicopathological features of BC. The connection between expression of Rab22a and clinicopathological characteristics of patients with BC was analyzed
High Rab22a expression is associated with the poor prognosis of patients with BC. In the Kaplan-Meier estimation, (Fig. 2d ). This indicates that patients with high expression of Rab22a had poorer OS. Univariate and multivariate Cox-regression analysis were conducted to identify factors related with OS of patients with BC (Table III) . The univariate Cox-regression analysis indicates that a high level of expression of Rab22a (P=0.003) and Her-2 (P=0.044) were related to poor OS. Then, a high level of expression of Rab22a (P= 0.003) was identified to be associated with short OS in the multivariate Cox-regression analysis. These results infer that Rab22a could be an independent predictor for Bc. 
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Univariate analysis
Multivariate analysis MCF-10A (P<0.001; Fig. 3A) . The results were confirmed at the protein level using western blotting analysis (Fig. 3B) . After a stable Rab22a shRNA knockdown cell line was established in SK-BR-3 cells, mRNA and protein levels of Rab22a were examined using RT-qPCR and western blotting, respectively ( Fig. 3c and d) . The mRNA level of Rab22a in SK-BR-3 shRNA2 and shRNA3 was 70% lower than that of the SK-BR-3 Sc (P<0.001). The proliferation of SK-BR-3 shRNA and SK-BR-3 SC cells were examined continuously for 96 h. It was found that Rab22a-shRNA showed a significantly lower proliferation rate than SK-BR-3 Sc cells (P<0.05; Fig. 3E ). Moreover, downregulation of Rab22a significantly inhibited the migration and invasion of Bc cells (P<0.05; Fig. 4) . The xenograft mice model showed that the tumor weight of Rab22a Sc and knockdown group was 0.86±0.11 g vs. 0.29±0.05 g (P<0.01; Fig. 5A and B) and tumor volume was 100.70±9.40 mm 3 vs. 53.67±8.09 mm 3 (P<0.05; Fig. 5c ) at the endpoint date. The results of the in vitro and in vivo experiments indicate that the proliferation ability of BC is significantly inhibited in Rab22a knockdown group, compared with the Sc group.
GSEA identifies the Rab22a-related signaling pathways. In order to recognize signaling cascades related with Rab22a in Bc, GSEA was employed to analyze pathways differentiated in the Rab22a high and low expressed data sets. GSEA indicated noteworthy changes (FdR<0.25, P<0.05) in the enrichment of the MSigDB Collection. The most significantly enriched signaling cascades based on NES values are presented in Fig. 6 . GSEA found that in the Rab22a overexpression group, 'E2F targets', 'G2M checkpoint', 'mammalian target of rapamycin complex 1 (mTorc1) pathway', 'protein secretion' and 'myc targets pathways' are upregulated ( Fig. 6A-E) , while 'hypoxia', 'KRas signal-down', 'tumor necrosis factor (TNF)-α signal via nuclear factor (NF)κB and p53 pathways' are downregulated ( Fig. 6F-I) . 
Discussion
A number of studies on the possible function of Rab22a have emerged during recent years (25, 26) . However, the role of Rab22a in Bc has not been discussed as much. In the present study, the correlation between Rab22a expression and clinicopathological characters and patient OS were examined. It was found that Rab22a is overexpressed in BC tissues and that high expression of Rab22a is an independent prognostic factor of Bc. Moreover, Rab22a was found to be required for the proliferation, migration and invasion of Bc cells.
Rab22a is a member of the RAS oncogene family and the protein encoded gene is a member of the RAB family of small GTPases. At present, >60 Rab members have been recognized (27) . The function of Rab proteins is regulated by the cycling of the proteins between GTP-bound active and GdP-bound inactive states, with the relative amount of these two small GTPase states regulated by GTPase-activating proteins and guanine nucleotide exchange factors (28) . Rab GTPases are considered the main regulators of secretory and endocytic pathways (29) . Endocytosis plays an imperative role in cellular processes, including nutrient uptake and receptor signaling (30). Some Rab GTPases function as membrane trafficking regulators and determine protein presentation for the neoplastic cell membrane (31) . Defective vesicular trafficking of growth factor receptors has been found to be a manifold hallmark of cancerous cells (32) . Rab22a has been reported to control the trafficking of recycling endosomes comprising clathrin-dependent factors, such as epidermal growth factor receptor, transferrin receptor protein 2, copper-transporting ATPase 1 and glucose transporter 4, as well as clathrin-independent factors, such as MHc-I, β2-adrenergic receptor and integrin b1 receptor are endocytosed cargoes to the cell surface in non-melanocytes (26) .
Rab22a is dysregulated in numerous cancer types. However, the prognostic value of Rab22a has not been previously investigated in BC. The present study found that Rab22a expression is related to clinical stage, N classification, nipple invasion, venous invasion and vital state. Increased expression of Rab22a in the present Bc cohorts is positively related to a poor prognosis in patients. In the current study, it was shown that Rab22a is an independent prognosis factor of Bc. Therefore, Rab22a may be a novel survival predictive biomarker for Bc. These findings suggest that the overexpression of Rab22a may act as a possible biomarker to identify Bc that may result in a poorer clinical outcome.
In order to investigate whether Rab22a affects Bc progression, Rab22a mRNA and protein levels were found to be upregulated in Bc cells compared with normal epithelium cells. Knockdown of Rab22a inhibits Bc cell proliferation in vitro and in vivo. Moreover, loss function of Rab22a expression decreases the migration and invasion capabilities of SK-BR-3 cells. The present findings are consistent with other research reports. Zhou et al (10) reported that Rab22a is overexpressed in lung cancer and that knockdown of Rab22a represses the migration and invasion of lung cancer cells. Moreover, Rab22a improves recycling of cluster of differentiation (cd)147 that is necessary for lung cancer cell migration and invasion. A further study performed by Qi et al (33) identified that the transmembrane protein, YIPY2, promotes cd147-medated malignant phenotypes by recruiting and activating Rab5 and Rab22a in hepatocellular carcinoma. Su et al (17) found that the increased expression of Rab22a is related to an advanced clinical stage in melanoma and shorter OS. The present study suggests that Rab22a may act as a novel oncogene in Bc and may be a potential therapeutic target.
Atypical and uncontrolled cell proliferation is a hallmark of malignancy and is triggered by the dysregulation of the expression of numerous vital proteins. Although emerging evidence shows the regulation between Rab22a and non-coding RNAs in different types of tumors (7, 34) , the regulatory mechanism of transcription or the signaling pathway of Rab22a is not well studied. Therefore, a GSEA analysis was performed to study the potential pathways related with Rab22a. GSEA analyses indicated that in the Rab22a overexpression group, 'E2F targets', 'G2M checkpoint', 'mTorc1 pathway', 'protein secretion' and 'myc target pathways' are upregulated, while 'hypoxia', 'KRas signal-down', 'TNF-α signal via NFκB and p53 pathways' are downregulated. A set of Rab proteins have been reported to promote tumor aggression by regulating intracellular signaling. The signaling pathway identified by GSEA is consistent with that of other published studies (35) (36) (37) . Overexpression of Rab1A promotes colorectal cancer progression and invasion by activating mTorc1 signaling. Moreover, it has been shown that Bc stem cell development is promoted by Rab2A through activation of extracellular signaling (38) . While low Rab1B expression is reportedly correlated with poor prognosis of Bc, downregulation of Rab1B was found to promote triple-negative breast cancer (TNBc) metastasis by activating transforming growth factor-β/mothers against decapentaplegic homolog signaling (39) . Hypoxia-inducible factors induces microvesicle (MV) generation by upregulating Rab22a expression in human BC cells. However, Rab22a knockdown abrogates MV generation under hypoxic conditions and impairs lung metastasis (40) . However, the detailed underlying mechanism still requires additional investigation. One limitation of the present research is the loss-function study was only performed in one cell line; further studies including gain-function will be conducted in multiple Bc cell lines.
In conclusion, this study has shown that Rab22a is overexpressed in human Bc tissues and cell lines, and is a prognostic biomarker that is required for cell progression. The present research suggests that Rab22a may be regarded as a possible biomarker of prognosis and treatment of Bc in the future.
